Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.

MLA

Kindler, Hedy L., et al. “Axitinib plus Gemcitabine versus Placebo plus Gemcitabine in Patients with Advanced Pancreatic Adenocarcinoma: A Double-Blind Randomised Phase 3 Study.” The Lancet. Oncology, vol. 12, no. 3, Mar. 2011, pp. 256–62. EBSCOhost, https://doi.org/10.1016/S1470-2045(11)70004-3.

APA

Kindler, H. L., Ioka, T., Richel, D. J., Bennouna, J., Létourneau, R., Okusaka, T., Funakoshi, A., Furuse, J., Park, Y. S., Ohkawa, S., Springett, G. M., Wasan, H. S., Trask, P. C., Bycott, P., Ricart, A. D., Kim, S., & Van Cutsem, E. (2011). Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. The Lancet. Oncology, 12(3), 256–262. https://doi.org/10.1016/S1470-2045(11)70004-3

Chicago

Kindler, Hedy L, Tatsuya Ioka, Dirk J Richel, Jaafar Bennouna, Richard Létourneau, Takuji Okusaka, Akihiro Funakoshi, et al. 2011. “Axitinib plus Gemcitabine versus Placebo plus Gemcitabine in Patients with Advanced Pancreatic Adenocarcinoma: A Double-Blind Randomised Phase 3 Study.” The Lancet. Oncology 12 (3): 256–62. doi:10.1016/S1470-2045(11)70004-3.